Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IG unapproved device probe

This article was originally published in The Gray Sheet

Executive Summary

HHS Inspector General further narrows its probe into billing for unapproved devices, dropping the off-label component of the investigation. In early June, the IG sent subpoenas to more than 100 hospitals seeking documentation related to billing for procedures done over the last 10 years with devices that had not been approved by FDA and approved devices used for off-label indications. The IG subsequently told hospitals that the probe would only focus on 10 types of cardiovascular devices produced by 23 manufacturers ("The Gray Sheet" June 27, p. 1). With the latest modification, hospitals will only be required to provide data on unapproved devices, not off-label indications. The IG also has extended the deadline for submitting documents to the end of August and has reduced the number of years that the subpoena covers

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel